Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Total Current Liabilities (2016 - 2025)

Vycor Medical has reported Total Current Liabilities over the past 16 years, most recently at $4.8 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 6.34% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, up 6.34% year-over-year, with the annual reading at $4.8 million for FY2025, 6.34% up from the prior year.
  • Total Current Liabilities was $4.8 million for Q4 2025 at Vycor Medical, down from $4.8 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $4.8 million in Q3 2025 and troughed at $3.0 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $3.9 million (2023), against an average of $3.9 million.
  • Year-over-year, Total Current Liabilities rose 17.57% in 2021 and then rose 5.76% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $3.1 million in 2021, then increased by 16.03% to $3.7 million in 2022, then grew by 11.48% to $4.1 million in 2023, then grew by 10.36% to $4.5 million in 2024, then increased by 6.34% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Total Current Liabilities are $4.8 million (Q4 2025), $4.8 million (Q3 2025), and $4.6 million (Q2 2025).